Summit Therapeutics (SUMM)

 

Latest News

Summit Therapeutics plc : Grant of Share Options

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

Summit Therapeutics plc : Exercise of Options

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

Summit Therapeutics File US Annual Report on Form 20-F

Miscellaneous medium priority announcements

Summit changes registered office

Summit Therapeutics has announced that the Company's registered office has changed to 136a Eastern Avenue, Milton Par...

All News

DateHeadlineSource
12-04-17Summit Therapeutics plc : Grant of Share OptionsRNS
10-04-17Summit Therapeutics plc : Exercise of OptionsRNS
31-03-17Summit Therapeutics File US Annual Report on Form 20-FRNS
30-03-17Summit changes registered officeStockMarketWire
30-03-17Summit Therapeutics plc : Change of Registered OfficeRNS
30-03-17Summit Therapeutics to Present at the Needham Healthcare ConferenceRNS
29-03-17Summit Therapeutics Reports 4th Quarter and Year End Financial Results and Operational ProgressRNS
27-03-17Summit schedules FY resultsStockMarketWire
27-03-17Summit to extend PhaseOut DMD clinical trialStockMarketWire
27-03-17Summit Therapeutics plc : Notice of ResultsRNS
27-03-17Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients with DMDRNS
15-03-17Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare ConferenceRNS
05-03-17Trends and Targets for 6/03/2017Trends and Targets
28-02-17Summit Therapeutics Recognises Tenth Annual Rare Disease DayRNS
23-02-17Summit Therapeutics plc : Exercise of WarrantsRNS
02-02-17Summit to take part in investor conferencesStockMarketWire
02-02-17Summit Therapeutics to Participate in February Investor ConferencesRNS
01-02-17Summit outlines Phase 3 programme for ridinilazoleStockMarketWire
01-02-17Summit Outline Phase 3 Programme for Novel CDI Antibiotic RidinilazoleRNS
25-01-17Summit Therapeutics plc : Holding(s) in CompanyRNS
19-01-17Summit Therapeutics plc : Exercise of OptionsRNS
18-01-17Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & DevelopmentRNS
15-12-16Summit Therapeutics plc : 3rd Quarter ResultsRNS
13-12-16Summit Therapeutics plc : Notice of ResultsRNS
16-11-16Summit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinical Trial of EzutromidRNS
24-10-16Summit Therapeutics plc : Exercise of OptionsRNS
19-10-16Summit Therapeutics plc : Holding(s) in CompanyRNS
14-10-16Summit Therapeutics plc : Exercise of OptionsRNS
11-10-16Summit Therapeutics plc : Exercise of OptionsRNS
07-10-16Summit Therapeutics plc : Exercise of OptionsRNS
06-10-16Summit Presents Preclinical DMD Data at 21st Congress of World Muscle SocietyRNS
04-10-16FTSE closes close to its record high StockMarketWire
04-10-16Why Summit Therapeutics just doubledInteractive Investor
04-10-16Summit Files Form 6-K on Licensing and Collaboration Agreement with Sarepta and Updated Cash GuidanceRNS
04-10-16Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement with SareptaRNS
04-10-16Sarepta Therapeutics and Summit Enter into Exclusive License and Collaboration AgreementRNS
28-09-16Summit Therapeutics plc : Holding(s) in CompanyRNS
27-09-16Summit Received Rare Pediatric Disease Designation from US FDA for Ezutromid in Treatment of DMDRNS
26-09-16Summit Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMDRNS
08-09-16Summit Therapeutics widens H1 lossStockMarketWire

RSS feeds

  • Editorial news feed for LSE:SUMM Editorial
  • Regulatory news feed for LSE:SUMM Regulatory